Search: onr:"swepub:oai:DiVA.org:uu-329722" >
Will sacubitril-val...
Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?
-
- Mair, Johannes (author)
- Med Univ Innsbruck, Dept Internal Med Cardiol & Angiol 3, Innsbruck, Austria.
-
- Lindahl, Bertil, 1957- (author)
- Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
-
- Giannitsis, Evangelos (author)
- Heidelberg Univ, Med Klin 3, Heidelberg, Germany.
-
show more...
-
- Huber, Kurt (author)
- Wilhelminen Hosp, Dept Med Cardiol & Intens Care Med, Vienna, Austria.
-
- Thygesen, Kristian (author)
- Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark.
-
- Plebani, Mario (author)
- Univ Hosp Padova, Dept Lab Med, Padua, Italy.
-
- Moeckel, Martin (author)
- Charite Univ Med Berlin, Div Emergency Med, Berlin, Germany.;Charite Univ Med Berlin, Dept Cardiol, Berlin, Germany.
-
- Mueller, Christian (author)
- Univ Hosp Basel, Dept Cardiol, Basel, Switzerland.;Univ Hosp Basel, Cardiovasc Res Inst Basel, Basel, Switzerland.
-
Jaffe, Allan S. (author)
-
show less...
-
Med Univ Innsbruck, Dept Internal Med Cardiol & Angiol 3, Innsbruck, Austria Kardiologi (creator_code:org_t)
- 2016-01-12
- 2017
- English.
-
In: European Heart Journal. - : Oxford University Press (OUP). - 2048-8726 .- 2048-8734. ; 6:4, s. 321-328
- Related links:
-
https://journals.sag...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Since the approval of sacubitril-valsartan for the treatment of chronic heart failure with reduced ejection fraction, a commonly raised suspicion is that a wider clinical use of this new drug may diminish the clinical utility of B-type natriuretic peptide testing as sacubitril may interfere with B-type natriuretic peptide clearance. In this education paper we critically assess this hypothesis based on the pathophysiology of the natriuretic peptide system and the limited published data on the effects of neprilysin inhibition on natriuretic peptide plasma concentrations in humans. As the main clinical application of B-type natriuretic peptide testing in acute cardiac care is and will be the rapid rule-out of suspected acute heart failure there is no significant impairment to be expected for B-type natriuretic peptide testing in the acute setting. However, monitoring of chronic heart failure patients on sacubitril-valsartan treatment with B-type natriuretic peptide testing may be impaired. In contrast to N-terminal-proBNP, the current concept that the lower the B-type natriuretic peptide result in chronic heart failure patients, the better the prognosis during treatment monitoring, may no longer be true.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- Sacubitril-valsartan
- natriuretic peptides
- B-type natriuretic peptide
- diagnosis
- heart failure
- acute cardiac care
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Mair, Johannes
-
Lindahl, Bertil, ...
-
Giannitsis, Evan ...
-
Huber, Kurt
-
Thygesen, Kristi ...
-
Plebani, Mario
-
show more...
-
Moeckel, Martin
-
Mueller, Christi ...
-
Jaffe, Allan S.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
European Heart J ...
- By the university
-
Uppsala University